• NL close

Nearly 60% of patients undergoing cancer treatment are estimated to have had at least one potential drug-drug interaction; for patients receiving oral anticancer therapy, up to 50% have been reported to experience a potential drug-drug interaction, with 16% experiencing a major event. Drug-drug interactions are therefore a significant issue for cancer patients and the health care professionals who treat them. Combining the internationally recognised drug-drug interactions expertise of the University of Liverpool (UK) with the clinical pharmacology in oncology and haemotology expertise of Radboud University, Nijmegen (the Netherlands), this site was established in 2017 in response to the need for improved management of DDIs with anti-cancer agents.

The Mitochondrial Disease Sequence Data Resource (MSeqDR) is a centralized genome and phenome bioinformatics resource built by the mitochondrial disease community to facilitate clinical diagnosis and research investigations of individual patient phenotypes, genomes, genes, and variants. It integrates community knowledge from expert‐curated databases with genomic and phenotype data shared by clinicians and researchers.

The EPSA | ERNICA Registry is to improve the quality of patient care by enabling health care providers to get insight in their outcomes and using the cumulative data from the EPSA registry to conduct scientific research, for example to compare treatments or identify certain risk factors for complications. The EPSA (European Pediatric Surgical Audit) registry contains information on diseases seen in new-born children, like: Hirschsprung’s disease, Congenital Diaphragmatic Hernia, Oesophageal Atresia, Anorectal Malformation, Omphalocele and Gastroschisis. ERNICA is the European Reference Network for rare Inherited and Congenital (digestive and gastrointestinal) Anomalies European Reference Networks and aims to pool together disease-specific expertise, knowledge and resources from across Europe to achieve health goals that may otherwise be unachievable in a single country. ERNICA monitors and evaluates its activities in accordance with the ERN-wide monitoring framework of expert healthcare professionals from specialised healthcare providers across Europe. These networks seek to pool together the expertise available across Europe and concentrate knowledge and resources on rare and/or complex diseases. Each ERN focuses on a particular rare disease area with two diagnostic groups: Malformations of the digestive system (oesophageal diseases, intestinal diseases, intestinal failure and gastroenterological diseases) and Malformations of the diaphragm and abdominal wall (Malformations of the diaphragm and Abdominal wall defects) This standard defines the metadata required to insure availability, versioning and interoperability of the EPSA|ERNICA data.

NARCIS provides access to scientific information, including (open access) publications from the repositories of all the Dutch universities, KNAW, NWO and a number of research institutes, which is not referenced in other citation databases.